Skip to main content

Table 4 Estimated effect (EE) and effect size (ES) of early engagement in Didactic Webinars

From: Expanding access to medications for opioid use disorder in primary care clinics: an evaluation of common implementation strategies and outcomes

  Early engagement with a prescriber vs. Did not engage Early engagement without a prescriber vs. Did not engage Early engagement with a prescriber vs. Early engagement without a prescriber
Q1 Q2 Q3 Q1 Q2 Q3 Q1 Q2 Q3
Reach
Number of patients on OUD
  EE (95% CI) −12.98 (−1565.22, 1539.26) −7.63 (−702.28, 687.03) −2.27 (−1554.45, 1549.91) −4.21 (−1829.63, 1821.21) 10.04 (−943.41, 963.50) 24.30 (−1801.41, 1850.00) −8.77 (−1190.90, 1173.36) −17.67 (−635.76, 600.43) −26.57 (−1209.28, 1156.15)
  ES (95% CI) −0.16 (−19.65, 19.33) −0.10 (−8.82, 8.63) −0.03 (−19.52, 19.46) −0.05 (−22.97, 22.87) 0.13 (−11.84, 12.10) 0.31 (−22.62, 23.23) −0.11 (−14.95, 14.73) −0.22 (−7.98, 7.54) −0.33 (−15.18, 14.52)
Number of patients prescribed MOUD
  EE (95% CI) −1.29 (−44.71, 42.13) 2.05 (−24.66, 28.77) 5.40 (−38.03, 48.82) 6.91 (−46.69, 60.51) 8.81 (−27.74, 45.37) 10.72 (−42.88, 64.32) −8.20 (−43.00, 26.61) −6.76 (−30.53, 17.02) −5.32 (−40.13, 29.48)
  ES (95% CI) −0.08 (−2.83, 2.67) 0.13 (−1.56, 1.82) 0.34 (−2.41, 3.09) 0.44 (−2.96, 3.83) 0.56 (−1.76, 2.87) 0.68 (−2.71, 4.07) −0.52 (−2.72, 1.68) −0.43 (−1.93, 1.08) −0.34 (−2.54, 1.87)
Percent of patients prescribed MOUDa
  EE (95% CI) 10.24 (0.28, 20.20) −8.34 (−16.26, −0.43) −26.93 (−35.23, −18.63) 8.15 (3.26, 13.03) −11.30 (−15.46, −7.15) −30.75 (−35.54, −25.96) 2.10 (−4.88, 9.07) 2.96 (−2.04, 7.95) 3.82 (−2.63, 10.28)
  ES (95% CI) 0.28 (0.01, 0.56) −0.23 (−0.45, −0.01) −0.75 (−0.98, −0.52) 0.23 (0.09, 0.36) −0.31 (−0.43, −0.20) −0.85 (−0.99, −0.72) 0.06 (−0.14, 0.25) 0.08 (−0.06, 0.22) 0.11 (−0.07, 0.29)
Adoption
Number of prescribers
  EE (95% CI) 1.40 (−2.89, 5.69) 0.40 (−3.37, 4.17) −0.60 (−4.89, 3.69) 2.06 (−3.34, 7.47) 1.53 (−3.34, 6.40) 1.00 (−4.41, 6.40) −0.66 (−4.30, 2.97) −1.13 (−4.42, 2.16) −1.60 (−5.24, 2.04)
  ES (95% CI) 0.75 (−1.56, 3.06) 0.21 (−1.81, 2.24) −0.32 (−2.63, 1.98) 1.11 (−1.80, 4.01) 0.82 (−1.80, 3.44) 0.54 (−2.37, 3.44) −0.36 (−2.31, 1.60) −0.61 (−2.38, 1.16) −0.86 (−2.82, 1.10)
Number of x-waivered prescribers
  EE (95% CI) 1.45 (0.02, 2.88) 1.80 (0.59, 3.01) 2.15 (0.72, 3.58) 1.24 (−0.62, 3.11) 0.87 (−0.77, 2.51) 0.49 (−1.37, 2.36) 0.21 (−0.91, 1.33) 0.93 (−0.04, 1.91) 1.66 (0.54, 2.78)
  ES (95% CI) 0.55 (0.01, 1.09) 0.68 (0.22, 1.14) 0.81 (0.27, 1.36) 0.47 (−0.24, 1.18) 0.33 (−0.29, 0.95) 0.19 (−0.52, 0.89) 0.08 (−0.35, 0.50) 0.35 (−0.02, 0.72) 0.63 (0.20, 1.05)
Number of active x-waivered prescribers
  EE (95% CI) 0.36 (−0.26, 0.99) 0.46 (−0.05, 0.96) 0.56 (−0.07, 1.18) 0.26 (−0.55, 1.08) 0.01 (−0.68, 0.70) −0.24 (−1.05, 0.58) 0.10 (−0.43, 0.63) 0.45 (0.00, 0.90) 0.79 (0.26, 1.32)
  ES (95% CI) 0.20 (−0.14, 0.53) 0.25 (−0.02, 0.52) 0.30 (−0.04, 0.64) 0.14 (−0.30, 0.58) 0.01 (−0.36, 0.38) −0.13 (−0.57, 0.31) 0.05 (−0.23, 0.34) 0.24 (0.00, 0.48) 0.43 (0.14, 0.71)
Percent of x-waivered prescribers
  EE (95% CI) 0.81 (0.36, 1.97) 5.62 (4.56, 6.68) 10.44 (9.27, 11.60) −1.44 (−2.78, −0.09) 0.55 (1.79, 0.68) 0.33 (1.02, 1.67) 2.24 (1.39, 3.09) 6.18 (5.39, 6.96) 10.11 (9.26, 10.96)
  ES (95% CI) 0.04 (0.02, 0.09) 0.26 (0.21, 0.30) 0.47 (0.42, 0.53) −0.07 (−0.13, −0.00) 0.03 (0.08, 0.03) 0.02 (0.05, 0.08) 0.10 (0.06, 0.14) 0.28 (0.25, 0.32) 0.46 (0.42, 0.50)
Implementation
IMAT implementation quality
  EE (95% CI) 0.05 (0.04, 0.14) 0.09 (0.21, 0.03) 0.14 (0.06, 0.22)
  ES (95% CI) 0.08 (0.06, 0.23) 0.15 (0.35, 0.05) 0.23 (0.10, 0.36)
  1. aPrimary outcome; EE and ES in bold indicated 95% CI did not cross zero